Appclon Registers U.S. Patent for Dual Antibody 'AM201', Secures Rights for Autoimmune Disease Treatment
Dual Antibody Targeting Both IL-6 and TNF-α
Includes Technology to Improve Manufacturing Quality Issues
Appclon announced on May 19 that it has completed registration of a U.S. patent related to the core technology of 'AM201', a candidate for an autoimmune disease treatment based on its dual antibody platform 'AffiMab'.
The registered patent covers a polypeptide with enhanced protein purity and antigen affinity, as well as antibody–antigen binding fragment complexes utilizing this polypeptide and their manufacturing methods.
AM201 is a dual antibody candidate designed to simultaneously inhibit IL-6 and TNF-α, which are considered key inflammatory mediators in autoimmune diseases such as rheumatoid arthritis. This represents a strategy to differentiate from existing single-target therapies.
The patent also includes a protein engineering technology to reduce glycosylation-related quality variations that can occur during antibody production. The company explained that this enables improvements in antibody homogeneity and binding properties.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Appclon representative stated, "This patent registration will serve as a foundation for future global commercialization and expansion of technology partnerships."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.